Patents Represented by Attorney, Agent or Law Firm Bret E. Field
-
Patent number: 6369046Abstract: This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating dementia. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating dementa in a human including a glucoccrticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocoticoid receptor antagonist.Type: GrantFiled: February 4, 1999Date of Patent: April 9, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Alan F. Schatzberg, Joseph K. Belanoff
-
Patent number: 6365129Abstract: A high throughput toxicology screening method is provided. In the subject method, at least 10 different compound compositions are tested simultaneously. Each compound composition is tested by contacting it with a plurality, e.g. from about 10 to 1000, of non-mammalian multi-cellular organisms and determining the effect of the compound composition on the organisms. The multi-cellular organisms employed in the subject methods are small, have differentiated tissues and organs and have a rapid generation time. The subject high throughput screening methods find use in a variety of applications, and are particularly suited for use in the toxicology screening of libraries of compounds, such as libraries of combinatorially produced compounds.Type: GrantFiled: December 27, 1999Date of Patent: April 2, 2002Assignee: Tosk, Inc.Inventor: Patrick Fogarty
-
Patent number: 6365365Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-3 or KSGal6ST, or homologues thereof.Type: GrantFiled: November 12, 1998Date of Patent: April 2, 2002Assignee: The Regents of the University of CaliforniaInventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
-
Patent number: 6362173Abstract: This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for ameliorating pathologies or conditions associated with psychosis. These pathologies or conditions include psychotic major depression, schizoaffective disorders, Alzheimer's Disease and cocaine addiction. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for the amelioration of psychosis in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.Type: GrantFiled: August 15, 2000Date of Patent: March 26, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Alan F. Schatzberg, Joseph K. Belanoff
-
Patent number: 6358917Abstract: This invention provides the use of Botulinum toxin (BTX) to cause paralysis of a depressor anguli oris (DAO) musculature in a patient to alleviate downturn at corners of the patient's mouth.Type: GrantFiled: August 24, 1999Date of Patent: March 19, 2002Inventors: Jean D. A. Carruthers, Alastair Carruthers
-
Patent number: 6352576Abstract: Methods are provided for the selective removal of CO2 from a multicomponent gaseous stream to provide a CO2 depleted gaseous stream having at least a reduction, e.g. 30 to 90%, in the concentration of CO2 relative to the untreated multicomponent gaseous stream. In practicing the subject methods, the multicomponent gaseous stream is contacted with an aqueous fluid, e.g. CO2 nucleated water, under conditions of selective CO2 clathrate formation to produce a CO2 clathrate slurry and CO2 depleted gaseous stream. A feature of the subject invention is that a CO2 hydrate promoter is employed, where the CO2 hydrate promoter is included in the multicomponent gaseous stream and/or the aqueous fluid. The CO2 hydrate promoter serves to reduce the minimum CO2 partial pressure required for hydrate formation as compared to a control. The subject methods find use in a variety of applications where it is desired to selectively remove CO2 from a multicomponent gaseous stream.Type: GrantFiled: March 30, 2000Date of Patent: March 5, 2002Assignee: The Regents of the University of CaliforniaInventors: Dwain F. Spencer, Robert P. Currier
-
Patent number: 6352829Abstract: Methods and compositions are provided for analyzing differences in the RNA profiles between a plurality of different physiological samples. In the subject methods, a set of a representational number of distinct gene specific primers is used to generate labeled nucleic acids from each of the different physiological samples. The labeled nucleic acids are then compared to each other and differences in the RNA profiles are determined. The subject methods find use in methods of identifying differential gene expression.Type: GrantFiled: January 5, 1999Date of Patent: March 5, 2002Assignee: Clontech Laboratories, Inc.Inventors: Alex Chenchik, George Jokhadze, Robert Bibilashvilli
-
Patent number: 6346098Abstract: Methods are provided for locally administering an agent to a host. Specifically, the subject methods provide for the local administration of an agent to an interstitial space of a host. In the subject methods, an agent is retroinfused into a vessel of a host, typically a vein, under conditions sufficient for the agent to enter an interstitial space of the host proximal to the vessel location into which the agent is retroinfused. In practicing the subject methods, the agent is administered to the host in combination with the production of vascular stress at the site of administration, where the vascular tissue stress is sufficient to provide for transport of the agent from the vascular site of deposition into the target interstitial space. In a preferred embodiment, the agent is retroinfused at a pressure sufficient to provide for mechanical stress on the vessel proximal to the target interstitial space. Also provided are kits for use in practicing the subject methods.Type: GrantFiled: March 7, 2000Date of Patent: February 12, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Paul G. Yock, Ali H. Hassan, Alan Ching Yeun Yeung, Andrew Carter, Mehrdad Rezaee, Niall Herity, Sidney Lo, Peter J. Fitzgerald
-
Patent number: 6344548Abstract: Nucleic acid compositions encoding polypeptide products with diglyceride acyltransferase activity, as well as the polypeptide products encoded thereby and methods for producing the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies and in the production of triacylglycerols.Type: GrantFiled: June 24, 1998Date of Patent: February 5, 2002Assignee: The Regents of the University of CaliforniaInventors: Robert V. Farese, Jr., Sylvaine Cases, Steven Smith, Sandra K. Erickson
-
Patent number: 6336772Abstract: Compositions for and method of degrading organic chemicals in soil. The composition is a nutrient medium serving as a substrate for micro-organisms in the soil, preferably containing a major proportion of a source of carbon skeleton and energy, a macronutrient component preferably including nitrogen and other macronutrients, and a micronutrient component, preferably also a complexing agent and a vitamin/co-factor component. This nutrient material is added to soil, e.g. soil contaminated by a pesticide, to cause proliferation of micro-organisms which are effective, or which develop effectiveness to degrade the organic chemicals. Preferably the micro-organisms are those naturally present in the soil but useful micro- organisms may be added with the nutrient medium.Type: GrantFiled: November 12, 1996Date of Patent: January 8, 2002Inventor: Thomas T. Yamashita
-
Patent number: 6326175Abstract: Methods and compositions are provided for producing full-length cDNA libraries. In the subject methods, full length first strand cDNAs are isolated using a fusion protein of an eIF-4E domain and an eIF-4G domain separated by a flexible linker. Also provided is the novel fusion protein employed in the subject methods, as well as nucleic acids encoding, and host cells capable of expressing, the same. Finally, kits for use in practicing the subject methods are provided. The subject invention finds use in a variety of applications in which full-length CDNA libraries are employed.Type: GrantFiled: July 13, 1999Date of Patent: December 4, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Karl Guegler, Ruoying Tan, Michael J. Rose
-
Patent number: 6318023Abstract: Composition for and method of stimulating growth of plants, e.g. increase in crop production. The composition comprises a carbon skeleton/energy component, typically a sugar or mixture of sugars; a macronutrient component providing the elements nitrogen, phosphorus, potassium and calcium, preferably also magnesium and sulfur; a micronutrient component providing zinc, iron and manganese, preferably also copper, boron, molybdenum and cobalt. The composition also preferably contains a vitamin/cofactor component and an enhancement component. The composition may be in the form of an aqueous solution or in a form suitable for coating seeds or coating pollen. It may be applied as a foliar spray, as a soil amendment, as a root dip or as an injectable solution. Preferably where, for example, it is used as a foliar spray it is applied at intervals at different stages of growth.Type: GrantFiled: July 13, 2000Date of Patent: November 20, 2001Inventor: Thomas T. Yamashita
-
Patent number: 6316690Abstract: Non-mammalian, transgenic animals, e.g. flies, that exhibit neoplastic phenotypes, i.e. spontaneously produce metastatic tumors, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, and particularly neoplastic, diseases. Finally, kits for screening compounds for anti-neoplastic activity are provided.Type: GrantFiled: December 27, 1999Date of Patent: November 13, 2001Assignee: Tosk, Inc.Inventor: Patrick Fogarty
-
Patent number: 6309440Abstract: Composition for and method of stimulating growth of plants, e.g. increase in crop production. The composition comprises a carbon skeleton/energy component, typically a sugar or mixture of sugars; a macronutrient component providing the elements nitrogen, phosphorus, potassium and calcium, preferably also magnesium and sulfur; a micronutrient component providing zinc, iron and manganese, preferably also copper, boron, molybdenum and cobalt. The composition also preferably contains a vitamin/cofactor component and an enhancement component. The composition may be in the form of an aqueous solution or in a form suitable for coating seeds or coating pollen. It may be applied as a foliar spray, as a soil amendment, as a root dip or as an injectable solution. Preferably where, for example, it is used as a foliar spray it is applied at intervals at different stages of growth.Type: GrantFiled: August 25, 1998Date of Patent: October 30, 2001Inventor: Thomas T. Yamashita
-
Patent number: 6306600Abstract: Green fluorescent protein (GFP) is widely used as a reporter in determining gene expression and protein localization. The present invention provides fusion proteins with a half life of ten hours or less with several embodiments having half lives of 4 hours or less. Such proteins may be constructed by fusing C-terminal amino acids of the degradation domain of mouse ornithine decarboxylase (MODC), which contains a PEST sequence, to the C-terminal end of an enhanced variant of GFP (EGFP). Fluorescence intensity of the fusion protein in transfected cells is similar to that of EGFP, but the fusion protein, unlike EGFP, is unstable in the presence of cycloheximide. Specific mutations in the MODC region have resulted in mutants with varying half lives, useful for a variety of purposes.Type: GrantFiled: July 30, 1999Date of Patent: October 23, 2001Assignee: Clontech Laboratories, Inc.Inventors: Steve Kain, Xianqiang Li
-
Patent number: 6303362Abstract: In vitro methods for making a recombinant adenoviral genome, as well as kits for practicing the same and the recombinant adenovirus vectors produced thereby, are provided. In the subject methods, the subject genomes are prepared from first and second vectors. The first vector includes an adenoviral genome having an E region deletion and three different, non-adenoviral restriction endonuclease sites located in the E region. The second vector is a shuttle vector and includes an insertion nucleic acid flanked by two of the three different non-adenoviral restriction endonucleases sites present in the first vector. Cleavage products are prepared from the first and second vectors using the appropriate restriction endonucleases. The resultant cleavage products are then ligated to produce the subject recombinant adenovirus genome. The subject adenoviral genomes find use in a variety of application, including as vectors for use in a variety of applications, including gene therapy.Type: GrantFiled: October 27, 1999Date of Patent: October 16, 2001Assignees: The Board of Trustees of the Leland Stanford Junior University, University of WashingtonInventors: Mark A. Kay, Hiroyuki Mizuguchi
-
Patent number: 6300073Abstract: Enzyme compositions, kits comprising the same and methods for their use in one-step RT-PCR are provided. The subject enzyme compositions at least include a mutant thermostable DNA polymerase and a mutant reverse transcriptase. In preferred embodiments, the mutant thermostable DNA polymerase is an N-terminal deletion mutant of Taq polymerase and the mutant reverse transcriptase is a point mutation mutant of MMLV-RT. The subject kits, in addition to the above described mutant thermostable DNA polymerase and mutant reverse transcriptase, at least include one of, and usually both of, dNTPs and a buffer composition, where the subject kits may further include additional reagents, including nucleic acids, a thermostabilizing agent, a glycine based osmolyte and the like. In practicing the subject methods, a reaction mix that at least includes template RNA, the above described mutant polymerase and reverse transcriptase, dNTPs, buffer, and nucleic acid primers is prepared.Type: GrantFiled: October 1, 1999Date of Patent: October 9, 2001Assignee: Clontech Laboratories, Inc.Inventors: Ningyue Zhao, Helmut Wurst
-
Patent number: 6300322Abstract: Artificial plasma-like solutions and methods for their use are provided. The subject solutions include: electrolytes and an oncotic agent. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute.Type: GrantFiled: May 5, 2000Date of Patent: October 9, 2001Assignee: BioTime, Inc.Inventors: Paul E. Segall, Hal Sternberg, Harold D. Waitz, Judith M. Segall
-
Patent number: 6291243Abstract: Novel P element derived vectors and methods for their use to insert an exogenous nucleic acid into the genome of a target cell are provided. The subject vectors have a pair of P element transposase recognized insertion sites, e.g. 31 base pair inverted repeats, flanking at least two transcriptionally active genes. In practicing the subject methods, a vector of the subject invention is introduced into the target cell under conditions sufficient for transposition to occur. The subject methods find use in a variety of applications in which the insertion of an exogenous nucleic acid into the genome of a target cell is desired, e.g. include research, synthesis and therapeutic applications.Type: GrantFiled: April 27, 2000Date of Patent: September 18, 2001Assignees: The Board of Trustees of the Leland Stanford Jr. University, Tosk, Inc.Inventors: Patrick Fogarty, Joseph Lipsick
-
Patent number: 6291652Abstract: Antibodies, as well as binding fragments and mimetics thereof, that specifically bind to polyglutamine expansion containing proteins, e.g. mutant huntingtin protein, are provided. The subject binding agents, e.g. antibodies, fragments and mimetics thereof, etc., are characterized in that they bind to the target polyglutamine expansion containing protein in a manner that differs from the 1C2 antibody, e.g. in terms of affinity, avidity, and the like. Also provided are methods of screening compounds for polyglutamine expansion protein binding modulation activity, as well as pharmaceutical compositions of such agents. In addition, methods and devices for screening samples for the presence of polyglutamine expansion containing proteins, e.g. mutant huntingtin protein, are provided. Finally, nucleic acids encoding the subject antibodies and methods for their expression, including in therapeutic treatment protocols, are provided.Type: GrantFiled: January 7, 2000Date of Patent: September 18, 2001Assignee: The Regents of the University of CaliforniaInventor: Steven Finkbeiner